Literature DB >> 2018068

Fragile X screening program in New York State.

S L Nolin1, D A Snider, E C Jenkins, W T Brown, M Krawczun, D Stetka, G Houck, C S Dobkin, G Strong, G Smith-Dobransky.   

Abstract

Most fragile X [fra(X)] males in New York State have not been identified. Hence, a large number of female relatives are unaware of their risks for having an affected child. A program was established in New York State in 1987 to screen for the fra(X) syndrome in mentally retarded males with living relatives. The goal of the program is to identify affected males and inform their families about the diagnosis. In this way relatives would be able to assess their risks for having a fra(X) male. In order to identify the males a screening form was developed to assess 10 features which included physical characteristics, behavior, and family history. Males who exhibited at least 5 of these manifestations were selected for cytogenetic analysis. Any male who had macroorchidism or a family history of mental retardation was also included. A total of 995 males have been screened of which 352 (35%) were selected for cytogenetic analyses. Seventeen (10.5%) of the 161 completed studies were positive for fra(X). A large number of possible female carriers were identified in the families of the propositi. This program identifies fra(X) males in a population of the mentally retarded for whom there had been no previous diagnosis. By using a two-step procedure, it is possible to screen a large population of the mentally retarded for fra(X) without testing each male cytogenetically.

Entities:  

Mesh:

Year:  1991        PMID: 2018068     DOI: 10.1002/ajmg.1320380218

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  2 in total

1.  Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel.

Authors:  H Toledano-Alhadef; L Basel-Vanagaite; N Magal; B Davidov; S Ehrlich; V Drasinover; E Taub; G J Halpern; N Ginott; M Shohat
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

Review 2.  Blood specimens from patients referred for cytogenetic analysis: Vanderbilt University experience from 1985 to 1992.

Authors:  M G Butler; T Hamill
Journal:  South Med J       Date:  1995-03       Impact factor: 0.954

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.